Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin

United States - English - NLM (National Library of Medicine)

x-gen pharmaceuticals, inc. - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or

United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals aps - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistin 150 mg in 2 ml - colistimethate for injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. colistimethate for injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection and other antibacterial drugs, colistimethate for injection should be used only to treat or prevent infections that ar

United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals usa llc - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or p

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistimethate for injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. colistimethate for injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate and other antibacterial drugs, colistimethate should be used only to treat or prevent infections that are proven or strongly suspecte

United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals usa llc - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or p